Beam Therapeutics (BEAM) Non Operating Investment Income (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Non Operating Investment Income data on file, last reported at $16000.0 in Q1 2026.

• On a quarterly basis, Non Operating Investment Income rose 100.77% year-over-year to $16000.0 in Q1 2026; TTM through Mar 2026 was $6.0 million, a 147.1% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 127.97% from the prior year.
• Non Operating Investment Income for Q1 2026 stood at $16000.0, up from -$3.3 million in the prior quarter.
• Over the last five years, Non Operating Investment Income for BEAM reached as high as $21.6 million in Q4 2022 and fell as low as -$12.8 million in Q1 2023.
• Historically, Non Operating Investment Income has averaged -$501588.2 across 5 years, with a median of -$2.1 million in 2024.
• On a YoY basis, Non Operating Investment Income climbed as much as 605.34% in 2022 and fell as far as 839.65% in 2022.
• Year by year, Non Operating Investment Income stood at $21.6 million in 2022, then slumped by 103.35% to -$722000.0 in 2023, then tumbled by 50.97% to -$1.1 million in 2024, then tumbled by 205.41% to -$3.3 million in 2025, then surged by 100.48% to $16000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Investment Income figures were $16000.0 in Q1 2026, -$3.3 million in Q4 2025, and $4.9 million in Q3 2025.